Shares of Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating) traded down 7.3% during trading on Tuesday . The company traded as low as $3.03 and last traded at $3.18. 13,899 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 54,272 shares. The stock had previously closed at $3.43.
Eterna Therapeutics Stock Performance
The stock has a 50 day moving average of $3.55.
Get Eterna Therapeutics alerts:Insiders Place Their Bets
In related news, Director Nicholas Jason Singer purchased 283,286 shares of the business's stock in a transaction on Friday, December 2nd. The stock was acquired at an average price of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at $873,181.92. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Eterna Therapeutics news, major shareholder John D. Halpern acquired 335,920 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was bought at an average price of $3.28 per share, with a total value of $1,101,817.60. Following the purchase, the insider now owns 450,961 shares of the company's stock, valued at $1,479,152.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nicholas Jason Singer acquired 283,286 shares of the business's stock in a transaction dated Friday, December 2nd. The stock was acquired at an average cost of $3.28 per share, with a total value of $929,178.08. Following the purchase, the director now directly owns 266,214 shares in the company, valued at approximately $873,181.92. The disclosure for this purchase can be found here. Corporate insiders own 20.50% of the company's stock.
About Eterna Therapeutics
(Get Rating)Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
See Also
- Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- The Institutions Choose CarMax Over Carvana, Should You?
- Heatmap in Trading: How to Learn What Market Depth Hides
- Micron Technology Sees Chip Recovery by the End of 2023
- Three Healthcare Penny Stocks to Watch In The New Year
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.